- Home
- TARS
as 03-26-2025 1:36pm EST
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $63.67 | AVG Volume (30 days): | 641.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.08 - $57.28 | Next Earning Date: | 05-07-2025 |
| Revenue: | $182,953,000 | Revenue Growth: | 948.62% |
| Revenue Growth (this year): | 90.93% | Revenue Growth (next year): | 46.04% |
Stock Insider Trading Activity of Tarsus Pharmaceuticals Inc. (TARS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Mar 24 '25 | Sell | $50.00 | 6,000 | $300,000.00 | 824,106 | |
| Whitfield Dianne C. | TARS | Chief Human Resources Officer | Mar 18 '25 | Sell | $47.93 | 6,711 | $321,323.02 | 46,355 | |
| Neervannan Seshadri | TARS | Chief Operating Officer | Mar 18 '25 | Sell | $47.93 | 7,583 | $363,141.50 | 84,660 | |
| Farrow Jeffrey S | TARS | See Remarks | Mar 18 '25 | Sell | $47.93 | 3,724 | $178,306.42 | 24,871 | |
| Mottiwala Aziz | TARS | Chief Commercial Officer | Mar 18 '25 | Sell | $47.93 | 10,565 | $505,856.42 | 68,422 | |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Mar 18 '25 | Sell | $47.93 | 24,216 | $1,163,050.13 | 824,106 |
Latest Tarsus Pharmaceuticals Inc. News
TARS Breaking Stock News: Dive into TARS Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
Daily – Vickers Top Buyers & Sellers for 03/24/2025
MT Newswires
6 days ago
Tarsus Pharmaceuticals Insider Sold Shares Worth $1,163,050, According to a Recent SEC Filing
MT Newswires
14 days ago
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
MT Newswires
14 days ago
Tarsus Pharmaceuticals Prices Upsized $125 Million Equity Offering
GlobeNewswire
14 days ago
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
GlobeNewswire
15 days ago
Tarsus Announces Proposed $100.0 Million Public Offering
GlobeNewswire
20 days ago
Tarsus to Participate in Upcoming Investor Conference
Thomson Reuters StreetEvents
a month ago
Q4 2024 Tarsus Pharmaceuticals Inc Earnings Call
Compare TARS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TARS Tarsus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.